AbbVie (ABBV) /Pharmacyclics (PCYC) Deal Bullish for SMID Biotech and Big Drugs, Says RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Nomura Downgrades Pharmacyclics (PCYC) to Neutral; Deal Supports Further M&A (INFI) (RCPT) (ICPT) (INCY) (NBIX) (GEVA)
March 5, 2015 1:15 PM ESTNomura Securities analyst M. Ian Somaiya downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral with a price target of $261.25 (from $196.00) after the company agreed to be acquired by AbbVie (NYSE: ABBV) at the same price.
Somaiya said the deal has positive implications for Neutral-rated... More
Analyst Calls AbbVie (ABBV) Takeover of Pharmacyclics (PCYC) 'Desperate'
March 5, 2015 11:14 AM ESTAbbVie (NYSE: ABBV) shares weakened Thursday after it announced a surprise deal to acquire Pharmacyclics (NASDAQ: PCYC) for $21 billion, or $261.25 per share. Previous rumors suggested Johnson & Johnson (NYSE: JNJ) would acquire the company.
In the view of many, including Bernstein's Geoffrey C. Porges, the... More
AbbVie (ABBV) to Acquire Pharmacyclics (PCYC) for $21 Billion
March 4, 2015 10:53 PM ESTAbbVie (NYSE: ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies. The acquisition accelerates AbbVie's clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership position in hematological oncology an attractive and rapidly growing market, now approaching $24 billion globally. The acquisition adds to AbbVie's already comprehensive pipeline and strong growth prospects.
Under the terms of the transaction, AbbVie will pay... More
